Botanix Pharmaceuticals
Botanix Pharmaceuticals is an Australian clinical dermatology company focused on developing and commercializing innovative treatments for common skin diseases. Their lead product candidate is Sofdra, a potential treatment for primary axillary hyperhidrosis, and they are also developing other products for acne and atopic dermatitis.
Short position
Botanix Pharmaceuticals (ASX:BOT) has 0.64% of its shares on issue reported as short positions as of 5 Oct 2026, or about 17,619,596 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has risen 0.42 percentage points. Its highest recorded short interest was 5.23% in July 2025. BOT is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Botanix Pharmaceuticals (BOT) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $33.8Mvs $5.8M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- −$69.8Mvs −$86.4M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.032vs −$0.047 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- +487.1%FY
- EPS YoY
- n/aTTM
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- 57.6%
- Operating margin
- −205.1%
- Net margin
- −206.4%
- FCF margin
- −191.1%
- ROE
- −96.4%
- ROA
- −59.4%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $11.8M
- Net debt / EBITDA
- n/a
- Current ratio
- 2.6×
- Interest cover
- −24.4×
- Cash dividends paid / net profit
- n/a
- Market cap
- $38.3M
- P/E
- n/a
- P/B
- 0.6×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $33.8M | $5.8M | $601.8K | $102.9K |
| Gross profit | $19.5M | $2.3M | $601.8K | $102.9K |
| Operating income | −$69.3M | −$86.3M | −$15.5M | −$12.8M |
| EBITDA | −$64.6M | −$82.2M | −$13.8M | −$9.0M |
| EBIT | −$66.9M | −$84.4M | −$13.9M | −$9.1M |
| Interest expense | $2.8M | $2.0M | $10.7K | $81.7K |
| Pretax income | −$69.8M | −$86.4M | −$13.9M | −$9.2M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$69.8M | −$86.4M | −$13.9M | −$9.2M |
| Net interest income | −$1.7M | −$93.8K | $65.1K | −$15.8K |
| EPS basic | −$0.032 | −$0.047 | −$0.009 | −$0.008 |
| EPS diluted | −$0.032 | −$0.047 | −$0.009 | −$0.008 |
| Shares | 2.73B | 1.96B | 1.81B | 1.31B |
Financial reports
The company's own filings, newest first
- Appendix 4E & Annual Report for the Year Ended 30 June 2026Annual Results26 Aug 2026via asx_announcements
- Botanix Quarterly Activities Report and Appendix 4C Q4 FY26Quarterly Report27 Jul 2026via asx_announcements
- Botanix Quarterly Activities Report and Appendix 4C Q3 FY26Quarterly Report29 Apr 2026via asx_announcements
- Botanix 2026 Half Year Investor PresentationHalf Year Results3 Mar 2026via asx_announcements
- Correction - Appendix 4DHalf Year Results2 Mar 2026via asx_announcements
- Appendix 4D and Half Year ReportHalf Year Results27 Feb 2026via asx_announcements
- Botanix Quarterly Activities Report and Appendix 4C Q2 FY26Quarterly Report27 Jan 2026via asx_announcements
- Botanix Quarterly Activities Report and Appendix 4C Q1 FY26Quarterly Report20 Oct 2025via asx_announcements
- Appendix 4E & Annual Report for the Year Ended 30 June 2025Annual Results29 Aug 2025via asx_announcements
- June 2025 Quarterly Activities Report and Appendix 4CQuarterly Report28 Jul 2025via asx_announcements
Showing 10 of 21 reports